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Differential Neuroproteomic and Systems
Biology Analysis of Spinal Cord Injury*□S
Ahmed Moghieb‡§, Helen M. Bramlett**‡‡, Jyotirmoy H. Das‡§§, Zhihui Yang‡§,
Tyler Selig‡, Richard A. Yost, Michael S. Wang**‡‡, W. Dalton Dietrich**‡‡,
and Kevin K. W. Wang‡§¶ ¶¶
Acute spinal cord injury (SCI) is a devastating condition
with many consequences and no known effective treat-
ment. Although it is quite easy to diagnose traumatic SCI,
the assessment of injury severity and projection of dis-
ease progression or recovery are often challenging, as no
consensus biomarkers have been clearly identified. Here
rats were subjected to experimental moderate or severe
thoracic SCI. At 24h and 7d postinjury, spinal cord seg-
ment caudal to injury center versus sham samples was
harvested and subjected to differential proteomic analy-
sis. Cationic/anionic-exchange chromatography, fol-
lowed by 1D polyacrylamide gel electrophoresis, was
used to reduce protein complexity. A reverse phase liquid
chromatography-tandem mass spectrometry proteomic
platform was then utilized to identify proteome changes
associated with SCI. Twenty-two and 22 proteins were
up-regulated at 24 h and 7 day after SCI, respectively;
whereas 19 and 16 proteins are down-regulated at 24 h
and 7 day after SCI, respectively, when compared with
sham control. A subset of 12 proteins were identified as
candidate SCI biomarkers - TF (Transferrin), FASN (Fatty
acid synthase), NME1 (Nucleoside diphosphate kinase 1),
STMN1 (Stathmin 1), EEF2 (Eukaryotic translation elonga-
tion factor 2), CTSD (Cathepsin D), ANXA1 (Annexin A1),
ANXA2 (Annexin A2), PGM1 (Phosphoglucomutase 1),
PEA15 (Phosphoprotein enriched in astrocytes 15), GOT2
(Glutamic-oxaloacetic transaminase 2), and TPI-1 (Triose-
phosphate isomerase 1), data are available via Pro-
teomeXchange with identifier PXD003473. In addition,
Transferrin, Cathepsin D, and TPI-1 and PEA15 were fur-
ther verified in rat spinal cord tissue and/or CSF samples
after SCI and in human CSF samples from moderate/
severe SCI patients. Lastly, a systems biology approach
was utilized to determine the critical biochemical path-
ways and interactome in the pathogenesis of SCI. Thus,
SCI candidate biomarkers identified can be used to cor-
relate with disease progression or to identify potential SCI
therapeutic targets. Molecular & Cellular Proteomics
15: 10.1074/mcp.M116.058115, 2379–2395, 2016.
Traumatic spinal cord injury (SCI)1 is an injury resulting from
an insult inflicted on the spinal cord. It can lead to the loss of
sensory and motor after injury, so it is an important cause of
neurologic disability after trauma, such as lifelong paralysis for
SCI patients (1, 2). It is estimated that 300,000 people in
North America are living with a spinal cord injury (SCI), and
12,000 to 20,000 new cases occur annually in the United
States (3).
It has been hypothesized that the pathologic process that
leads to acute traumatic spinal cord injury consists of two
steps; the primary injury is the physical and mechanical dam-
ages that occur as a result of direct impact to the spinal cord.
The secondary injury is the cascade of biochemical events
such as proteolysis of cytoskeletal, membrane, and myelin
proteins due to the elevation in intracellular Ca2 that acti-
vates cysteine proteases (e.g. calpain). The proteolysis dam-
ages the spinal cord by progressive tissue degeneration,
including neuronal cell death, axonal degeneration, and de-
myelination in the spinal cord (4, 5). Although it is quite easy
to diagnose acute traumatic SCI, assessment of injury sever-
ity is often challenging. Neurological examinations are cur-
rently used for diagnosis, determination of severity, and pre-
diction of neurologic outcome in the brain injury (traumatic
brain injury (TBI), Stroke). However, these measures often
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cannot assess the severity of SCI; in addition, the neurological
recovery variability for SCI patients is high. Therefore, the
discovery and use of biomarkers for SCI could lead to devel-
opment of new therapeutic interventions that can be applied
to prevent or reduce disability of SCI (6).
A biomarker is defined, according to the National Academy
of Sciences, as an indicator that signals events in biological
samples or systems. Biomarkers are considered as extremely
valuable unbiased tools to define the severity of SCI because
they reflect the extent of the spinal cord damage and predict
neurologic recovery (7). There are some metabolite candi-
dates such as N-acetyl aspartate (NAA, neuronal/axonal
marker) (8), creatine (gliosis marker) (9), and choline (indicator
of cellular turnover related to both membrane synthesis and
degradation) (10) that can be used as biomarkers for moni-
toring the pathobiological changes of primary and secondary
damage in SCI using proton magnetic resonance spectros-
copy (1H-MRS). In vivo 1H-MRS is a valuable tool for nonin-
vasive monitoring of brain biochemistry by quantifying the
changes in the metabolites in brain tissue. However, due to
the relatively small size of the spinal cord and magnetic sus-
ceptibility effects from the surrounding bony structures, the
ability to acquire MR spectra with adequate signal -to-noise
ratio (SNR) is limited, and this precludes the detection of
subtle changes in metabolite levels (11).
Proteomic analysis is a useful technique for simultaneously
determining multiple proteins in a biological system; it pro-
vides robust methods to study protein abundance, expression
patterns, interactions, and subcellular localization in the
blood, organelle, cell, tissue, organ or organism that can be
studied to provide accurate and comprehensive data about
that system (12). Proteomic methods are the most powerful
techniques that can aid in the discovery of novel biomarker
candidates; it utilizes extensive sample procedure and Data
Dependent Acquisition to follow disease-specific proteins
(identity and concentration). It facilitates the identification of
all differentially expressed proteins at any given time in a
proteome and correlates these patterns with the healthy ones
during disease progression (13). It has been used to study
protein expression at the molecular level with a dynamic
perspective that helps to understand the mechanisms of the
disease (14). The complexity, immense size and variability of
the neuroproteome, extensive protein-protein and protein-
lipid interactions, all limit the ability of the mass spectrometer
to detect all peptides/proteins contained within the sample;
further, some peptides/proteins are extraordinarily resistant to
isolation (15, 16). Therefore, the analytical methods for the
separation and identification of peptides/proteins must man-
age all of these issues by using separation techniques com-
bined with the powerful new mass spectrometry technologies
to expand the scope of protein identification, quantitation and
characterization.
The complexity of the biological sample can be reduced by
further separation or fractionation at the protein or peptide
level. Multidimensional LC can be used for two or more dif-
ferent types of sequential combinations to improve signifi-
cantly the resolution power and results in a larger number of
proteins to be identified (17). Ion-exchange chromatography
(IEC) in the first dimension is very suitable for the separation of
proteins and peptides, separating proteins based on their
differences in overall charges. IEC’s stationary phase is either
an anion or a cation exchanger, prepared by immobilization of
positively or negatively charged functional groups on the sur-
face of chromatographic media, respectively. Proteins or pep-
tide separation occurs by linear change of the mobile-phase
composition (salt concentration or pH) that decreases the
interactions of proteins with the stationary phase, resulting in
finally eluting the proteins (18). Also, SDS-PAGE can be used
for further protein separation by apparent molecular weight
with the resolving distance optimized for the proteome of
interest. Furthermore, peptides can be separated by their
hydrophobicity using a reversed phase C18 column, which
can be directly coupled to the electrospray mass spectrom-
eter (ESI-LC-MS/MS). Reversed-phase liquid chromatogra-
phy (RPLC) is most often used in the second dimension due to
its compatibility with the downstream mass spectrometry
(sample concentration, desalting properties, and volatile sol-
vents). Proteomics has two approaches: “bottom-up”, which
involves direct digestion of a biological sample using a pro-
teolytic enzyme (such as trypsin) that cleaves at well-defined
sites to create a complex peptide mixture, followed by anal-
ysis of the digested samples on platforms that include liquid
chromatography prior to tandem mass spectrometry (LC-MS/
MS); and “top-down”, that involves separating intact proteins
from complex biological samples using techniques such as
liquid chromatography or 2-D gel electrophoresis, followed by
differential expression analysis using spectrum analysis or gel
imaging platforms. Although top-down analysis preserves
protein-protein interactions and does not lose the protein
information, it has been limited because of the difficulty in
intact protein processing due to the lack of separation meth-
ods (only gel based) (19, 20) as well as the challenges of
performing mass spectrometry on intact high-molecular
weight proteins.
Mass spectrometry (MS) is the most important tool for
protein identification and characterization in proteomics due
to the high selectivity and sensitivity of the analysis (1, 2, 16).
Electrospray ionization (ESI) is considered as an ideal ioniza-
tion source for protein analysis due to two characteristics:
first, the ability to produce multiply charged ions from large
molecules (producing ions of lower m/z that are readily sep-
arated by mass analyzers such as quadruples and ion traps),
and second, the ease of interfacing with chromatographic
liquid-phase separation techniques (21). Electrospray ioniza-
tion followed by tandem mass spectrometry (ESI-MS/MS) is
one of the most commonly used approaches for protein iden-
tification and sequence analysis (18). Proteomic studies have
been conducted to identify biomarkers and assess severity of
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SCI utilizing traumatic animal SCI models (16, 22–24), but
these methods have not been used to identify biomarkers in
CSF from patients with traumatic SCI because CSF sampling
is challenging (25–27).
Calcium binding protein S100 beta (S100), glial fibrillary
acidic protein (GFAP), myelin basic protein (MBP), neuron
specific enolase (NSE), neurofilament protein- H and L (NF-H,
NF-L), SBDP150/SBDP145/SBDP120, ubiquitin C-terminal
hydrolase-L1 (UCHL-1), microtubule- associated 2 (MAP-2),
and cytokines interleukins 6 and 8 (IL-6 and IL-8) have been
identified as potential markers of spinal cord damage mainly
in the cerebrospinal fluid (CSF) compartment (6, 26–36).
These studies need to be developed and validated for their
potential use in clinical settings to determine the severity of
SCI. However, due to the complexity of spinal cord injury,
multiple interventions targeting different complications of
damage may be required. Human SCI is a heterogeneous
injury with injuries potentially occurring at different spinal cord
segments and injury severities. Thus, it is unlikely that a single
biomarker can be successfully used to diagnose and deter-
mine the severity of SCI patients.
Systems biology (SB) is a new field of science that analyzes
the relationships among all the individual components in a
biological system (genes, proteins, metabolites etc.) by quan-
titative description of the interaction among them (37). The
goal of this approach is to develop computational models of
these systems, therefore the responses of the system to any
kind of perturbation; for example, environmental disturbance,
genetic mutation etc., can be predicted. Pathway analysis of
various biomarker types have been or can be used to revealed
association with CNS disorders; including neurodegenerative
disorders, stroke, traumatic brain injury (TBI) and spinal cord
injury (SCI) (38–40).
In this study, we sough to identify possible new SCI mark-
ers by using our CAX-PAGE-LC-MS/MS proteomic platform
(41) using SCI biosamples collected from both an SCI animal
model (weight-drop) and human clinical studies of SCI
patients.
EXPERIMENTAL PROCEDURES
Rat Spinal Cord Injury Model—Adult female Fischer rats (220–250
g) were housed according to the National Institutes of Health and
United States Department of Agriculture guidelines. Institutional An-
imal Care and Use Committee of the University of Miami approved all
animal procedures. Prior to surgery, rats were anesthetized (45 mg
ketamine/kg, 5 mg xylazine/kg) by intraperitoneal injection. An ade-
quate level of anesthesia was determined by monitoring the corneal
reflex and withdrawal to painful stimuli for hind limbs. All animals
underwent T9-T10 spinal laminectomy (42, 43). During surgery, rats
were placed on a warming pad to maintain body temperature at
37°  0.5 °C. Briefly, the rat was placed ventrally on top of a small bit
of sterile gauze to evaluate the surgical site presenting an adequate
exposure of the back anatomy. A 2 cm longitudinal skin incision was
centered over the T9 spinus process along the midline. As previously
described, perispinal nerves and ligaments were laterally dissected
and retracted followed by removal of bony elements of the posterior
spine including the spinus process in lamina using a micro Rongiers.
The ninth thoracic spinal segment was then exposed without remov-
ing the dura mata by removing the dorsal part of the vertebra. The
exposed cord was next contused by a 10 gm weight dropped from a
height of either 12.5 mm (moderate), or 25 mm (severe) by using the
New York University (NYU)-MASCIS impactor (44). This model and
injury severities have been shown to produce well-described pattern
of electrophysiological, behavioral and histopathological conse-
quences (45).
Rat SCI-CSF Collection—Following SCI, CSF samples were drawn
at 4, 24 or 48 h posttrauma. CSF was collected as previously de-
scribed (46). At appropriate time points, injured, sham-injured and
naïve animals were anesthetized as described above and secured in
a stereotactic frame with the head allowed to move freely along the
longitudinal axis. The head was flexed so that the external occipital
protuberance in the neck was prominent and a dorsal midline incision
was made over the cervical vertebrae and occiput. The atlanto-
occipital membrane was exposed by blunt dissection and a 25-gauge
needle attached to polyethylene tubing was inserted into the cisterna
magna. Approximately 0.1 to 0.15 ml of CSF was collected per rat,
then they were removed and immediately euthanized by decapitation.
CSF samples were centrifuged at 4000  g for 4 min. at 4 °C to clear
any contaminating erythrocytes.
Sample Preparation—SCI and sham control (caudal, rostral and
epi-center segments) samples were rapidly snap frozen in liquid
nitrogen and homogenized to fine powder using a small mortar
and pestle set over a dry ice. The powder was scraped into chilled
microfuge tubes, then lysed with 1% Triton X-100 lysis buffer con-
taining 20 mM Tris HCl pH 7.4, 150 mM sodium chloride (NaCl), 5 mM
ethylenediaminetetraacetic acid (EDTA), 5 mM ethylene glycol
bis(aminoethyl ether) tetraacetic acid (EGTA), 10 l 1 M dithiothreitol
(DTT), 100 l of phosphatase inhibitors (all from Sigma-Aldrich), with
a complete mini protease inhibitor mixture tablet (Roche Biochemi-
cals). Lysis was conducted for 3 h at 4 °C with hourly vortexing.
Lysates were then centrifuged to remove DNA, lipids, and particulates
at 15,000  g for 10 min at 4 °C. The supernatant was collected and
protein content was determined using a DC Protein Assay (BioRad)
then, the protein concentration was standardized to 1 g/l for im-
munoblotting analysis. Pooled 1-mg SCI and control rostral segment
samples (n  5) were prepared for differential analysis using
CAX-PAGE.
Human Spinal Cord Injury Subject Enrollment and Biosample Col-
lection—Spinal cord injury subjects (SCI) classified as moderate-
severe (AIS Grades A, B & C) (n  15) were recruited at the University
of Miami Hospital for this SCI biomarker study. This human SCI study
is considered discovery stage and the candidate biomarkers are at
exploratory/discovery stage. The University of Miami Institutional Re-
view Board approved all human SCI studies (IRB#20090655). In this
discovery stage study, fifteen consented moderate-severe SCI sub-
jects were continuously enrolled during the period from August 2010
to September 2014. Patients were classified according to the Amer-
ican Spinal Injury Association scale (AIS) of impairment (degree of
impairment) and AIS on discharge (improvement), urodynamic test
(bladder control), somatosensory evoked potential test, and magnetic
resonance (MRI) scan. The patients were further classified as trau-
matic paraplegia or traumatic quadriplegia. (See supplemental Table
S1). SCI patients with confirmed moderate-severe SCI (AIS Grades A,
B, and C) are included. Subjects with pre-existing neurological or
neuropsychiatric conditions were excluded. Of the 15 SCI patients, 13
are male and 2 were female with an average of 38.5-year-old (range
19 to 67).
For CSF collection, we followed the NIH/NINDS common data
elements (CDE) for traumatic brain injury (https://commondatael-
ements.ninds.nih.gov/tbi.aspx) under the section ”TBI Biospecimen
Collection Protocol”, since biosample collection CDE has not been
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formally established for SCI. Briefly, strict aseptic techniques were
conducted when a lumbar puncture was performed at L2–3 or L3–4
and an intrathecal catheter inserted for intrathecal drainage of CSF.
Timed CSF samples were diverted to glass tubes (no preservative,
heparin or EDTA) for the specified vol. (3 cc), spun at 4000 RPM at
room temperature (to remove loose cells and debris). Aliquots of 500
l of cleared CSF (supernatant) were placed into 1.2 ml cryovials and
stored at –80 °C in an ultralow temperature freezer until used. In this
study, CSF samples were collected within every 6 h postinjury up to
6 days, whenever feasible.
In parallel, normal control CSF samples (n  20; 14 male, 6 female,
average age 42.0) were obtained from a commercial source (Biorec-
lamation Inc., Westbury, NY).
Gel Electrophoresis and Electrotransfer—2 Laemmli sample
buffer containing 65.8 mM Tris (pH 6.8), 0.1 mM DTT, 2% SDS, 0.01%
bromphenol blue and 10% glycerol in distilled water was used for
processing the control and SCI injured samples. Twenty (20) micro-
gram of protein from each sample was centrifuged for 1 min at 10,000
g and then resolved by SDS-PAGE on 4–20% or 10–20% Tris/glycine
gels (Invitrogen Life Technologies, Carlsbad, CA) at 200 V for 60 min
at room temperature. The fractionated proteins were transferred to a
polyvinylidene difluoride (PVDF) membrane (Invitrogen) by electro-
blotting using the iBlot Gel Transfer Device (Invitrogen) for 7 mins.
Following the transfer, the membranes were blocked in 5% nonfat dry
milk in TBST (20 mM Tris-HCl, 150 mM NaCl and 0.003% Tween-20,
pH 7.5) for an hour.
Immunoblotting Analysis and Antibodies—Immunoblotting mem-
branes containing tissue protein were incubated with the primary
antibody overnight at 4 °C with shaking. Monoclonal anti-mouse
-spectrin (Enzo Life Sciences NY, Farmingdale, NY), polyclonal anti-
rabbit GFAP (Abcam, MA, Cambridge, MA), and monoclonal anti-
mouse UCHL-1 (EMD Millipore, MA, Billerica, MA) were used at a
dilution of 1:1000 in 5% milk. Polyclonal anti-rabbit transferrin (Ab-
cam), polyclonal anti-goat cathepsin D (Santa Cruz Biotechnology,
Dallas, TX), polyclonal anti-rabbit triosephosphate isomerase-1
(TPI-1, TIM) (Santa Cruz Biotechnology), and polyclonal anti-rabbit
astrocytic phosphoprotein (PEA-15) (Cell Signaling, Danvers, MA)
were used at a dilution of 1:500, 1:200, and 1:1000, respectively in 5%
milk. On the following day, the membranes were washed three times
with TBST and probed with an alkaline phosphatase-conjugate goat
secondary antibody (EMD Millipore) at a dilution of 1:5000 in 5% milk
for an hour, followed by TBST washing. Immunoreactivity was de-
tected using 5-bromo-4-chloro-3-indolylphosphate (BCIP)/nitroblue
tetrazolium phosphatase substrate (Kirkegaard & Perry Laboratories,
Gaithersburg, MD). For all spinal cord tissue Western blots data, we
have included probing a house keeping protein polyclonal anti-car-
bonic anhydrase-II (Abcam) at dilution of 1:2000 in 5% milk as a
loading control. Since its lane-to-lane intensity variability is less than
20%, it was not necessary to convert the target protein densitometric
level as standardized relative levels over carbonic anhydrase-II.
CSF (like serum and plasma) is considered a biofluid, often when
biomarkers are measured in biofluids, they are expressed as a con-
centration unit i.e. per volume unit of a biofluid, e.g. in pg/ml or ng/ml),
rather than standardized over same amount of total protein concen-
tration. Thus, following this convention, our biomarker levels were not
standardized over the total protein concentration of the sample.
Lastly, CSF protein concentrations also tend to change after brain
injury - thus our CSF protein biomarker levels are measured in 10 l
of CSF sample.
Anion/Cation-Exchange Chromatography—The CAX chromatogra-
phy was performed on a BioRad Biologic DuoFlow system (Fig. 2)
with sulfoproyl SCX (S1) and quaternary ammonium SAX (Q1) modi-
fied Sepharose pre-packed ion-exchange columns (BioRad) that were
placed in series, and connected in tandem along with a QuadTec UV
detector and BioFrac fraction collector. Buffers consisted of 20 mM
Tris-HCl (pH 7.5 molecular biology grade, Fisher Scientific) in double
distilled water (mobile phase A) and 20 mM Tris-HCl with 1 M NaCl
(Fisher Scientific, crystalline 99.8% certified) in double distilled water
(mobile phase B). Samples of 1 mg proteins from pooled spinal cord
tissue lysates were injected with an optimized method for differential
analysis. The first and second linear gradient steps were from 0 to 5%
B, and 5 to 10% in 5 ml each at a flow rate of 1 ml/min, and followed
by a six-step gradient, each step increased by 5% from 10 to 40% in
1 ml, the last gradient step was from 40 to 50% in 1 ml. Then, the
composition was held at 50% B for 1 ml and re-equilibrated to 0% B
in 3 ml. The UV chromatograms were monitored at a wavelength of
280 and 214 nm for each run. Forty-four 1-ml fractions were auton-
omously collected via the BioFrac fraction collector into 1.5-ml screw-
cap microfuge tubes kept on ice.
1D-SDS-PAGE—Fractions collected throughout CAX chromatog-
raphy were concentrated using Millipore centrifugal ultrafiltration units
(Millipore Corporation) which have a retaining power for proteins of
3kDa. Each ultrafiltration unit was treated with 500 l of 1% SDS
(passivation for improved recovery) and soaked for three hours at
room temperature, and then all the device units were rinsed with tap
water followed by distilled water and spun at 15,000 rpm for 20 min
twice. The collected fractions (0.5 ml) were added to the ultrafiltration
units and spun at 15,000 rpm for 50 min at 4 °C. 2 Laemmli buffer
(containing 65.8 mM Tris (pH 6.8), 0.1 mM DTT, 2% SDS, 0.01%
bromphenol blue and 20% glycerol in distilled water) was added (20
l) for each unit and boiled for few seconds prior to collection by
centrifugation at 1000 g for 3 min. The protein fractions were run
side-by-side (i.e. sham next to SCI 6h & SCI 24h), by loading 20 l of
each fraction onto a Criterion TGX Any kDa gels (BioRad), 1 mm wide,
for 20 min at 300V in a Tris-glycine buffer.
Gel Band Visualization and Quantification—The gels were visual-
ized with Coomassie blue stain (BioRad) for differential band analysis.
Scanning of the gel and membrane bands was performed using an
Epson Expression 8836XL high-resolution flatbed scanner (Epson).
UN-SCAN-IT software (version 6.1, Silk Scientific Corporation) was
used for quantitative densitometric analysis of selected gel or mem-
brane bands based on their relative intensities. Fold increase or
decrease between differential bands was computed by dividing the
greater value by the lesser value with a positive sign and negative sign
to indicate an increase or decrease after SCI injury. Differential bands
were boxed and labeled according to their 2D-position. Gel band
intensity was quantified by NIH ImageJ software.
In-Gel Digestion of Proteins—Gels were thoroughly rinsed twice
with Optima LC-MS grade water. Differential bands were excised, cut
into pieces, placed in 1.5 ml low retention Eppendorf tubes, and
washed with 100 l Optima LC-MS H2O. The gel bands were washed
again by 50% 100 mM ammonium bicarbonate (Fisher)/50% aceto-
nitrile (Burdick-Jackson, Optima LC-MS grade). Bands were dehy-
drated with 100% acetonitrile and dried by Speedvac (Labcoco), and
then they were rehydrated with 50 l of 10 mM dithiothreitol, DTT
(Thermo) in 50 mM ammonium bicarbonate and incubated for 30 min
at 56 °C. DTT was replaced by 50 l of 55 mM iodoacetamide (Am-
ersham Biosciences) in 50 mM ammonium bicarbonate and reacted
for 30 min in the dark at room temperature for alkylation. Gel pieces
were washed with 50 mM ammonium bicarbonate followed by 100%
acetonitrile dehydration and dried by Speedvac. For protein diges-
tion, gel pieces were rehydrated with 15 l of 12.5 ng/l trypsin
solution (Promega Gold) for 30 min at 4 °C, and then 20 l of 50 mM
ammonium bicarbonate was added and incubated overnight at
37 °C. The hydrophobic peptide extraction was performed with
50% acetonitrile/50% water with 0.1% formic acid. The peptide
extract was dried by Speedvac and resuspended in 20 l Optima
LC-MS grade H2O with 0.1% formic acid after sonication for 15 min
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and centrifuged at 1500 rpm. Trypsinized band extracts were ana-
lyzed by nanospray reversed-phase liquid chromatography and
tandem mass spectrometry.
Reversed-Phase Liquid Chromatography Tandem Mass Spectrom-
etry (RPLC-MS/MS)—Nano-reversed-phase liquid chromatography
tandem mass spectrometry was employed for protein separation and
identification. Nanoflow was performed on a NanoAcquity UPLC (Wa-
ters, Milford); the autosampler was used to load two microliters of
each sample onto a 5 m particle size Symmetry 180 m  20 mm
C18 trapping column at 4 l/min for 10 min. Then, the sample plug
was loaded onto a 1.7 M particle size BEH130 C18 100 m  100
mm analytical column at 300 nL/min. The mobile phase consisted of
solvent A (water with 0.1% formic acid) and solvent B (acetonitrile
with 0.1% formic acid). Separation was achieved within a run time of
115 min at a flow rate of 300 nL/min. The first linear gradient was from
1% to 40% B over 90 min, the second linear gradient was from 40%
to 100% B over 5 min and held for 5 min before returning to initial
mobile-phase composition (1%B). Tandem mass spectra were col-
lected on LTQ-XL (Thermo, San Jose, CA) using a Data Dependent
Acquisition method in Xcalibur 2.0.7 (Thermo), in which data depend-
ent scanning was specified as a criteria to select the top 10 most
abundant ions using 11 separate scan events at a given chromato-
graphic time point (115 min) for subsequent analysis. The mass
spectrometer was set to perform a full-scan and subsequently
MS/MS scans on the ten most intense ions in the full-scan spectrum
MS (scan event 1) with Dynamic Exclusion enabled. Dynamic Exclu-
sion temporarily puts a mass into an exclusion list after its MS/MS
spectrum is acquired, providing the opportunity to collect MS/MS
information on the second most intense ion from the full-scan spec-
trum MS (scan event 1). All MS/MS spectra were analyzed using
Proteome Discoverer 1.3 (Thermo). SEQUEST (version: 1.3.0.339) and
X! Tandem (version: CYCLONE (2010.12.01.1)). Database search
engines were set up to search a trypsin-Indexed uniprot-Rattus
norvegicus.fasta (unknown version, 35126 entries). The search was
achieved using the average mass for matching the precursor with a
fragment ion mass tolerance of 0.8 Da and a parent ion tolerance of
2.00 Da and a maximum of two missed cleavage sites. Carbamidom-
ethylation of cysteine was selected as a static modification,
whereas the oxidation of methionine was selected as a dynamic
modification. Using the output from SEQUEST and X! Tandem,
Scaffold (version: Scaffold_3.3.3, Proteome Software) was used to
validate, organize, and interpret mass spectrometry data. Peptide
identifications were accepted if they could be established at greater
than 95.0% probability as specified by the Peptide Prophet algo-
rithm (38). Protein identifications were accepted if they could be
established at greater than 99.9% probability and contained at least
2 identified peptides. The mass spectrometry proteomics data have
been deposited to the ProteomeXchange Consortium via the PRIDE
(47) partner repository with the dataset identifier PXD003473 and
10.6019/PXD003473.
Systems Biology Tools—Pathway Studio software 9.0 (Ariadne
Genomics Inc. MD) and STRING (http://string-db.org/) were em-
ployed to identify significant pathways across individual samples as a
signature to predict clinical outcomes. Twelve SCI candidate bio-
markers (Table III) were input separately into Pathway Studio for
systems biology analysis. The network was generated using the
“Shortest Path” algorithm to map interactions between altered pro-
teins based on a comprehensive database from the relevant scientific
literature.
Experimental Design and Statistical Rationale—Rats to receive se-
vere spinal cord injury, moderate spinal cord injury, sham control, or
naïve control were selected randomly. There are total of 10 groups
(Naïve, sham 4 h, sham 24 h, sham 7 day, moderate SCI 4 h,
moderate SCI 24 h, moderate SCI 7 day, severe SCI 4 h, severe SCI
24h, severe SCI 7d) with n 5 rat each. Epicenter of impact segment,
rostral segment and caudal segment of the spinal cord tissue samples
were collected to prepare tissue lysate (n  5 each), respective rat
CSF samples were also collected (n  5).
For the LC-mass spectrometry, a portion of each rostral tissue
lysate sample (n  5) were pooled for these groups: sham 24 h,
severe SCI 24 h, sham 7 day severe SCI 7 day within the same group
were pooled to achieve 1 mg sample for the CAX-PAGE and LC-
MS/MS as described. For the verification of hits, individual un-pooled
samples (n  5) from rat rostral, caudal, and epicenter segments
spinal cord tissue lysates and CSF samples from all 10 groups (Naïve,
sham 4 h, sham 24 h, sham 7 day, moderate SCI 4 h, moderate SCI
24 h, moderate SCI 7 day, severe SCI 4 h, severe SCI 24 h, severe SCI
7 day) (n  5 for all cases) were subjected to Western blot analysis
and quantified by densitometry. n  5 is considered generally ac-
ceptable for this type of rodent proteomic and quantitative immun-
blotting analysis (41). For statistical tests, the main comparison is
control (naïve of sham at same time point) to SCI (either severe or
moderate). Thus we used unpaired t test, as we have performed
previously with a similar traumatic brain injury study (48). Also, we
performed severe SCI versus moderate SCI companion by unpaired t
test. p value of  0.05 is considered statistically significant for these
comparisons.
For human study, SCI patients were enrolled continuously at Uni-
versity of Miami Hospital when they met the enrollment criteria. A total
of n 15 SCI patients were enrolled for this study, serial CSF samples
were collected from first day of injury to up to 6 days from injury every
6 h (maximal 4 samples per day). For human control samples, n  20
human CSF non-injured controls were randomly selected (Biorecla-
mation Inc., Westbury, NY) and processed as with human SCI CSF
samples. For statistical tests of human samples, the main comparison
of quantitative immunoblot data is control CSF versus human CSF -
first sample or all CSF samples. Thus we used unpaired t test, as we
have performed previously with a similar TBI study (41). p value of 
0.05 is considered statistically significant for these comparisons.
RESULTS
CAX-PAGE Differential Neuroproteomic Analysis—CAX
chromatography was employed to fractionate SCI samples
and control proteins according to their surface charges fol-
lowed by 1D gel electrophoresis to separate proteins based
on their molecular weight. Pooled spinal cord tissue lysate
samples of rostral segment collected from the SCI rat contu-
sion model SCI (severe injury) at 4 h, 24 h, and 7 day time
points (n  5, each) were first subjected to CAX chromatog-
raphy ion exchange (CAX separation has the ability of retain-
ing both positively and negatively charged proteins). As
shown in Fig. 1, there were chromatographic differences with
high protein recovery for differential expression profiling of
sham and SCI rat lysates (UV chromatograms at a wavelength
of 280 nm), which were attributed to the injured spinal cord
proteome. Both sham and SCI proteins were distributed into
28 fractions (1 ml) and collected after using tandem CAX
columns. Protein fractions were analyzed side-by-side on a
1D-gel for differential comparison, 24 h sham versus 24 h SCI
and 7 day sham versus 7 day SCI. Differential bands were
boxed and labeled according to their 2D position with number
and letter (e.g. the top band excised from the lane of fraction
X was labeled XA). ImageJ densitometry software was used
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for quantification of selected differential gel band intensities to
derive the relative fold increase or decrease.
Identification of Differential Proteins by RPLC-MS/MS—Dif-
ferentially displayed bands were selected from the 1D-gels
and cut into pieces for proteomic analysis, then trypsinized.
The tryptic peptides were separated by reversed-phase liquid
chromatography online with tandem mass spectrometry
(RPLC-MS/MS) for protein identification. All MS/MS spectra
were analyzed using Proteome Discoverer 1.3 (Thermo),
SEQUEST and X! Tandem database search engines have
been utilized to search the experimental spectra against a
rat-indexed database and validated by Scaffold 3 (0.1% and
0.4% FDR for proteins and peptides, respectively). Based on
identified unique peptides, sequence coverage, and molecu-
lar weight gel band, the protein biomarker candidates were
isolated in each band.
41 and 38 proteins for 24h and 7d, respectively reported in
Tables I and II were identified by the analysis to be differen-
tially expressed between sham and SCI. The identified pro-
teins were grouped as having increased (22 and 22 proteins)
or decreased (19 and 16 proteins) abundance for 24 h and 7
day, respectively (Fig. 2). The proteins with increased levels
post-SCI (24 h) included aldehyde dehydrogenase 4 family,
member A1 (Aldh4a1) protein (Fragment), LOC367586 pro-
tein, aminoacylase-1A, transketolase, Gamma-enolase, elon-
gation factor 2, protein Tln1, and peroxiredoxin-2. After 7 day
the list included aldo-keto reductase family 1, member B10
(aldose reductase), pyruvate kinase PKM, Acyl-CoA synthe-
tase family member 2, mitochondrial, and protein-L-isoaspar-
tate (D-aspartate O-methyltransferase). Among the proteins
with decreased levels post-SCI (24 h) were isocitrate dehy-
drogenase [NADP], mannose-6-phosphate isomerase, pyri-
FIG. 1. CAX-PAGE differential separation of sham and SCI rat lysate (A) Ion exchange (CAX) separation chromatograms overlay of
pooled rat SCI (at 24 h and 7 day postsevere injury) and sham at 24 h and 7 day lysate (pooled from n  5 each) with the same 280
nm absorbance scale: sham in purple and SCI in green, solvent B % in orange, and conductivity in red. B, 1D-PAGE of selected CAX
fractions out of 28 collected, run side by side for comparison, selected bands are boxed and labeled according to 2D position. C, Quantification
of selected differential gel band intensities to derive the relative -fold increase or decrease using ImageJ densitometry software.
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doxal kinase, stathmin, and peripheral myelin protein 2
(Pmp2). After 7 day, alcohol dehydrogenase [NADP()], L-lac-
tate dehydrogenase B chain, ribosyldihydronicotinamide de-
hydrogenase [quinone], and ATP citrate lyase, isoform CRA a.
Some differentially expressed proteins are common in both
24h and 7d time points, annexin A1& A2, glyceraldehyde-3-
phosphate dehydrogenase, Pgm1 protein (Fragment), gluta-
thione S-transferase Mu 5, triosephosphate isomerase, and
transferrin (serotransferrin). Also, we have noticed the pres-
ence of the same proteins that were identified in both up and
down regulated bands. This can be explained as families of
proteins (Ex: annexin 1&2), mobility in CAX or PAGE would
TABLE 1
Identification of Differentially Expressed Proteins of sham and SCI rat lysate (24h) using CAX-PAGE/RPLC-MS/MS platform
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TABLE II
Identification of differentially expressed proteins of sham and SCI rat lysate (7days) using CAX-PAGE/RPLC-MS/MS platform
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vary with (protein modification, or altered by proteases (BDP)
so these proteins could elute in different fractions due to
differences in surface charge. Between the 24 h and 7 day SCI
increased protein level groups; we found that 7 of them over-
lapped (glyceraldehyde-3-phosphate dehydrogenase, Alco-
hol dehydrogenase [NADP()], annexin A2, Pgm1 protein,
triosephosphate isomerase (TIM), glutathione S-transferase
Mu 5, serotransferrin (transferrin)). Between the 24 h and 7
day post-SCI decreased protein level groups, only two pro-
teins were on both lists (annexin A2 and Pgm1 protein)
(Fig. 2).
Protein Immunoblotting Validation—Because necrosis,
apoptosis, and cell death pathways are activated early after
SCI damage, we have targeted already known biomarkers,
II- spectrin breakdown products (SBDP) SBDP-150 and
SBDP-145 as reporters of calpain-mediated necrotic injury,
SBDP-120 as a marker for caspase-mediated apoptosis, and
GFAP breakdown products GBDP-38 as reporters of calpain-
mediated glial injury, UCH-L1 for neuronal injury to validate
the potential value of the new identified candidates. The can-
didate protein selection was based on the spinal cord spec-
ificity, antibody availability, and levels of peptide abundance.
Five biomarker candidates were selected, blood brain barrier
(BBB) located transferrin (49), lysosomal protease cathepsin D
(50), triosephosphate isomerase-1 (TIM, TPI-1) (16), astrocytic
phosphoprotein of 15 kDa (PEA-15) (51), and potential stroke
biomarker nucleoside diphosphate kinase A (52) to confirm
their protein alterations associated with SCI. The proteolytic
damage markers to the spinal cord structural and cellular
components have been validated by quantitative immunoblot-
ting using specific antibodies for each protein. Differential
changes in the above mentioned proteins have been con-
firmed by using (tissue lysate and CSF) sham and SCI (4 h,
24 h and 7 day) groups in the two severity points (moderate
and severe) in rat spinal cord tissue segments (rostral, caudal,
and epicenter) and CSF (Fig. 3, Fig. 4, Fig. 5, 6).
In rat spinal cord tissue samples, two known neuronal/
axonal injury markers alpha-II-spectrin breakdown products
(SBSP150, 120) were observed and glial injury marker GFAP
was significantly degraded to GBDP-38K after SCI in both a
severity-dependent manner (severe  moderate) and time
dependent manner (7 day  24 h  4 h). No significant
changes of a third marker UCH-L1 was observed in spinal
cord tissue after SCI. For new candidate markers, the trans-
ferrin and PEA-15 levels are elevated in injured SCI samples
compared with sham in the three time points (Fig. 3–5). CathD
was found to be up-regulated only at 7 day post-SCI in all
three segments (Fig. 3–5). However, TPI-1 is not significantly
altered in this case.
In rat CSF, following SCI, marked increases of alpha II-
spectrin breakdown products, SBDP145, SBDP120, and
GFAP breakdown products, GBDP-38K were observed in 4h
and to a lesser extent in the 24h samples and they return to
FIG. 2. Comparison of differential SCI protein identification for
24 h and 7 day post-SCI versus sham. Shown are the number of
identified proteins using CAX-PAGE-LC-MS/MS platform along with
common proteins between 24 h and 7 days (A) up-regulated (B)
down-regulated.
FIG. 3. SCI-tissue immunoblotting validation (epi-center seg-
ment). A, Time course of post-SCI biomarkers and new candidates
validation illustrated by Western blot of rat spinal cord tissue (rostral)
lysate of rostral section (sham, and two SCI severity) collected at
three time points (4 h, 24 h, and 7 days), candidate markers probed
include transferrin, cathepsin D, TPI-1,and PEA-15. Western blot of
carbonic anhydrase II served as a loading control. B, Immunoblotting
quantification of spinal cord tissue lysate samples (sham and two SCI
severity levels at three time points) for transferrin, CathD, TPI-1,and
PEA-15 biomarkers. Mean  S.E. are shown. (* p  0.05, compared
with corresponding sham, unpaired t test).
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basal levels by 7 day, when compared with shams. This
temporal profile is different from the spinal cord tissue levels
of SBDP and GBDP patterns where their levels continue to
rise at 7 day. The most likely explanation is that at the tissue
level there may be some residual necrotic/apoptotic tissue
remaining and some continuing tissue damage and protein
breakdown during the early time points, but by day 7, the
animals might have sufficiently recovered to the point that
they can more efficiently remove extracellular biofluid-based
proteins (e.g. phagocytosis by microglia, macrophage) and
regain protein clearance mechanisms in the CSF compart-
ment, thus not allowing significant accumulation of the re-
leased biomarker proteins into the circulating CSF. Our novel
candidate markers TPI-1 displayed higher levels in both mod-
erate and severe (4 h and 24 h), however, PEA-15 didn’t show
signals. Transferrin was endogenously present in controls
(sham), but its levels were further elevated at 4h after SCI
(moderate and severe) (Fig. 6).
In human CSF, the calpain-generated SBDP150/145 levels
were elevated at day 1–2 and sustained to day 4–5; however,
the caspase-3-generated SBDP120 levels were elevated only
at day 4–5 (Fig. 7). This is consistent with the acute pro-
necrosis-calpain activation and delayed activation of
caspase-3 in the apoptosis phase of CNS injury (53, 54).
GFAP is subjected to endogenous proteolysis after SCI as it is
shown in Fig. 7. In addition, we have demonstrated strong
elevation of GFAP-BDP and to a lesser extent intact GFAP in
CSF from day 1 to day 5 after SCI. Novel marker candidates
Transferrin, CathD, TPI-1 and to a lesser extent, PEA-15, were
readily detected in human CSF samples, especially after SCI
(Fig. 7). CSF levels of all four candidate markers are also
significantly increased after in SCI as compared with control
CSF.(Fig. 8).
Systems Biology Analysis—Top 12 candidate SCI biomark-
ers are input into Systems Biology (SB) analysis (Pathway
Studio 10.0) to identify cellular process, regulation and com-
mon disease pathways. Using “Shortest Path” algorithm, po-
tential interactions among these protein components were
mapped (Fig. 9). Several nonredundant converging pathways
are identified - they highlight the potential role of neuronal
death mechanism, cell invasion, oxidative stress, and cell
differentiation pathway as main players on SCI. Additional
FIG. 4. SCI-tissue immunoblotting validation (caudal segment).
A, Time course of post-SCI biomarkers and new candidate’s valida-
tion illustrated by Western blot of rat spinal cord tissue (rostral) lysate
of rostral section (sham, and two SCI severity) collected at three time
points (4 h, 24 h, and 7 days), candidate markers probed include
transferrin, cathepsin D, TPI-1, and PEA-15. Western blot of carbonic
anhydrase II served as a loading control. B, Immunoblotting quanti-
fication of spinal cord tissue lysate samples (sham and two SCI
severity levels at 3 time points) for transferrin, CathD, TPI-1, and
PEA-15 biomarkers. Mean  S.E. are shown. (* p  0.05, compared
with corresponding sham, unpaired t test).
FIG. 5. SCI-tissue immunoblotting validation (rostral segment).
A, Time course of post-SCI biomarkers and new candidates validation
illustrated by Western blot of rat spinal cord tissue (rostral) lysate of
rostral section (sham, and two SCI severity) collected at three time
points (4 h, 24 h, and 7 days), candidate markers probed include
transferrin, cathepsin D, TPI-1 and PEA-15. Western blot of carbonic
anhydrase II served as a loading control. B, Immunoblotting quanti-
fication of spinal cord tissue lysate samples (sham and two SCI
severity levels at 3 time points) for transferrin, CathD, TPI-1, and
PEA-15 biomarkers. Mean  S.E. are shown. (* p  0.05, compared
with corresponding sham, unpaired t test).
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data and literature-mining and new experiments can be done
to further understand the pathological pathways involved in
spinal cord structural and functional changes, SCI recovery,
complications and other SCI-related co-morbidities. Impor-
tantly further analysis identified three pathways as altered
when the 12 SCI biomarker proteins as input. These include
(1) cell growth and aging, (2) metabolic dysfunction, and (3)
neural death pathways (Fig. 10). Lastly, Systems Biology anal-
ysis was also performed based on STRING program (http://
string-db.org/) of the top 12 SCI biomarkers plus known CNS
injury biomarkers, including II-spectrin (SPTAN1 in human
and rat, SPAN2 in mouse), UCHL1, MBP, GFAP, and S100b;
we identified several interactome clusters in human, rat and
mouse (Fig. 11). Overall, such SB analysis can help identify
convergent pathways that might be relevant to SCI pathology
and with future work we could identify possible therapeutic
targets.
DISCUSSION
Acute spinal cord injury (SCI) is a devastating disease with
many consequences and no known effective treatment. Al-
though it is quite easy to diagnose traumatic SCI, the assess-
ment of injury severity and projection of disease progression
or recovery are often challenging. In the literature, a number of
CNS structural proteins (NSE, S100b, NF-H) and inflammatory
cytokines (e.g. IL-6, IL-8) have been examined in proximal
biofluids such as CSF and microdialysate in human or in rat
model of SCI. However, no informative biomarkers have been
definitely identified.
Proteomics is a promising approach for biomarker discov-
ery; it has been used to study protein expression at the
molecular level with a dynamic perspective (41). In fact, Lu-
bieniecka et al. examined rat CSF fluid with LC-MS/MS ap-
proach and identified three proteins - Ywhaz (14–3-3 protein
zeta/delta), Itih4 (Inter--trypsin inhibitor heavy chain 4), and
FIG. 6. Rat SCI-CSF immunoblotting validation. A, Time course of post-SCI biomarkers release and new candidate marker validation
illustrated by Western blot of rat spinal cord CSF samples (sham, and two SCI severity) collected at three time points (4 h, 24 h, and 7 days),
the markers probed are alphaII-spectrin, transferrin, GFAP, TPI-1, UCHL-1, and PEA-15, B, Immunoblotting quantification of CSF samples
(sham and two SCI severity levels at three time points) for Alpha II-spectrin breakdown products SBDP145 & SBDP120, GFAP and GFAP-BDP
(38K), TPI-1, and PEA-15 biomarkers. Mean  S.E. are shown. (* p  0.05, compared with corresponding sham, unpaired t test).
FIG. 7. Representative time course of SCI biomarker candidate proteins released into human CSF after SCI, detected by immuno-
blotting. AlphaII-spectrin, SBDP150/145 and SBDP120, GFAP, GFAP-BDP, and Transferrin, CathD, TPI-1 and PEA-15 for two SCI patients A
&B at different time points postinjury and for two patients and 4 controls.
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Gpx3 (glutathione peroxidase 3) (7). However, none of these
three proteins are known to be specific or enriched in the
spinal cord of CNS. In this study, a comprehensive multi-dimen-
sional separation scheme, cationic/anionic-exchange (CAX)
chromatography, followed by 1D polyacrylamide gel electro-
phoresis (PAGE), has been used to reduce protein complexity
(Fig. 1, 2). A reverse phase liquid chromatography-tandem mass
spectrometry (LC-MS/MS) proteomic platform was utilized to
examine and characterize proteome changes associated with
rat SCI tissue (Table I, II). In all, 32 proteins were found to be
either up- or down-regulated at 24h after SCI (severe) in the
rostral segment of rat SCI, when compared with sham control
(Fig. 2). Similar, 29 additional proteins were either up- or down-
regulated at 7 day after SCI (Fig. 2). We thus further triage the
candidates down to 12 candidates in terms of signal strength as
well as potential relevance to spinal cord injury (Table III).
To confirm the authenticity of the candidates, we sought to
use a method for validation that is independent of mass
spectrometry. Quantitative immunoblotting method was cho-
sen (38) for these purposes. We also expanded the analysis
with three regions (rostral, caudal and epicenter) of SCI in-
jured (and sham) samples collected from the rat SCI animal
model at two severity-levels (moderate and severe). Tissue
samples collected were expanded to three time points (4 h,
24 h, 7 day) along with cerebrospinal fluid (CSF). With four the
12 candidate biomarkers, we were able to obtain robust im-
munoblotting signals (transferrin, CathD, TPI-1, and PEA-15)
(Fig. 3–5). We indeed verified that two proteins Transferrin and
PEA-15 are up-regulated at least one time point post-SCI in all
three tissue segments (Fig. 3–5). Their direction of change (i.e.
elevations) is consistent with the findings in mass spectrom-
etry data for both of these proteins (Table I, II). CathD was
found to be up-regulated only at 7d post-SCI in all three
segments (Fig. 3–5). These data are consistent with mass
spectrometry data showing CathD differential elevations only
at day 7 but not day 1 (Table II). We noted that while trans-
ferrin, CathD, TPI-1 and PEA-15 were up-regulated in both
moderate and severe SCI at various time points over naïve
and corresponding sham controls, but their levels between
the severe groups and corresponding moderate groups were
not different.
In our moderate injury model in rats, Transferrin and CathD
protein levels were elevated at the lesion epicenter as well as
caudal to the lesion site at 7 days, but were not significantly
increased in the rostral segments at the same time point (Fig.
3, 4 versus 5). This differs from the severe injury model, where
Transferrin and CathD were elevated in all three segments at
7 days. These findings may suggest that alterations in levels
of some proteins (e.g. Transferrin, CathD) might result from
neurodegenerative events occurring within the epicenter and
descending neural tracts rather than from secondary injury
processes which are likely to occur in epicenter, descending
and ascending tracts. In the future, it will be important to
correlate these and other biomarker changes and region de-
pendent structural changes with MRI imaging approaches to
evaluate cause and effect relationships.
In addition, we also examined with immunoblotting method
three candidate markers (transferrin, TPI-1 and PEA-15) in rat
SCI and naïve and sham control CSF samples collected at 4 h,
24 h, and 7days against two known CNS injury biomarkers
(II-Spectrin and GFAP and their breakdown products
(BDPs)). Although we did not get sufficient signals for PEA-15,
we readily detected transferrin and TPI- signals. Again, we
confirmed that transferrin is significantly up-regulated at 4 h
post-SCI (both moderate and severe), while TPI-1 was ele-
vated in CSF at 4 and 24 h postinjury (both moderate and
severe SCI) (Fig. 6). These data are consistent with spinal
tissue immunoblotting data (Fig. 3–5) as well as mass spec-
trometry data (Table I-II).
For our clinical translational study, we examined several
candidate biomarkers with immunoblotting method using se-
rial CSF samples (collected from day 1 to 5 postinjury) from 15
human, severe to moderate, SCI patients and 10 normal con-
trols (Suppl. Table I). Blood (serum, plasma) samples were not
FIG. 8. Quantification of biomarker release human CSF after SCI.
(A) Biomarker levels at initial time point (First sample taken- usually
within 36 postinjury) and all time points (all samples from day 0 to 6
post-SCI). Transferrin (signals  1⁄4 is shown), CathD, TPI-1, and
PEA-15 (signals 25 is shown). (* p 0.05, **, p 0.001, as compared
with control CSF, unpaired t test). B, Time course of biomarker levels in
CSF for all patients (n  14). Mean  S.E. are shown. Trend lines shown
are moving averages of biomarker levels from two adjacent time points.
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attempted due to unfavorable noise to signal issue. Transfer-
rin, CathD, TPI-1 and to a lesser extent, PEA-15, were readily
detected in human CSF samples, especially after SCI (Fig. 7).
From our composite quantification data, we were able to
establish their time course of release over 6 days postinjury
(Fig 8B). We also confirmed that all four markers were signif-
icantly elevated in CSF samples from SCI patients when com-
pared with corresponding controls (Fig 8A).
From comparing two different patients (e.g. SBDP, Trans-
ferrin, GFAP and TPI-1 (Fig. 7), it becomes apparent patient A
has an immediate elevation of these proteins at early time
points, while patient B has more fluctuated and persistent
elevated levels. It is tempting to suggest that these biomarker
profiles might reflect differences in severity (ASIA scale), le-
sion level (e.g. cervical versus lumbar), patient improvement
over time, and/or presence of secondary insults at later time
points. But due to the limited patient sample size, our current
discovery study did not have enough power to examine these
possible correlations systemically. This is in fact a limitation of
the current study.
For the four candidate biomarkers we validated in human
CSF samples, transferrin is a glycoprotein involved in binding
and regulation of free iron ion in tissue biofluids. Its up-
regulation after SCI might suggest that iron regulation might
be altered. Cathepsin D (CathD), a lysosomal cysteine prote-
ase, might be involved in the cytoskeletal and other cellular
protein degradation we observed after SCI. Two known cyto-
skeletal proteins (axonal II-spectrin and astroglial GFAP)
were already found to be degraded to respective BDPs after
SCI in rat and human (Fig. 6–7). TPI-1 (Triosephosphate
isomerase-1) is an enzyme that catalyzes the isomerization of
glyceraldehyde 3-phosphate (G3P) and dihydroxy-acetone
phosphate (DHAP) in glycolysis and gluconeogenesis. In ad-
dition to its role in glycolysis and gluconeogenesis TPI-1 is
also involved in several additional metabolic biological pro-
cesses including the pentose phosphate shunt, and fatty acid
biosynthesis. Thus, its up-regulation after SCI suggests likely
alterations of the regulation of metabolic pathways. PEA-15 is
a phosphorylation-regulated astroglia protein. The PEA-15
protein is shown to regulate autophagy via activation of JNK
in glioma cells (50). Its up-regulation suggests the involve-
ment in astroglia responses in SCI. However, regardless of
the proteomic methods used, it is nearly impossible to
detect all proteins that are altered in a given experimental
system, thus we also turned to Systems Biology (SB)
method to complement and expand our findings. SB anal-
ysis has the advantage of highlighting cellular process, reg-
ulation, common disease pathways as well as potential
protein-protein interactions.
Bioinformatic and Systems biology tools have been initially
developed to cancer biology based on the large cancer biol-
ogy datasets collected (55, 56). However, more recently, as
more neuro-disorder datasets are becoming available, these
bioinformatic and SB tools were being increasingly used in
neurological (TBI), neurodegenerative (multiple sclerosis,
amyotrophic lateral sclerosis (ALS)) and neuropsychiatric dis-
orders (substance abuse disorder) (38, 40, 57–59) and SCI in
the current study (Fig. 9–11).
FIG. 9. Candidate SCI biomarker input for Systems Biology and pathway network analysis. Top 12 candidate SCI biomarkers (shown
in (A)) are input into Pathway Studio to identify cellular process, regulation and common disease pathway analysis (B).
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When the 12 candidate biomarkers were input into SB
analysis, we indeed identified that at least three pathways
might be involved in SCI pathology: (1) cell growth and aging;
(2) metabolic dysfunction, and (3) neural death pathways (Fig.
9–10). In terms of interactome analysis, we also found that the
12 new SCI biomarkers we identified in fact interact with 5
known CNS injury biomarkers (SPTAN1 UCHL1, MBP, GFAP,
and S100b) by way of 2–3 clusters of interactome (Fig. 11).
Thus, such SB analysis can facilitate the identification of
convergent pathways and potential therapeutic target “hot-
spots” that might be critical to SCI pathology.
In conclusion, twelve SCI candidate biomarkers were tenta-
tively identified by out proteomic method. This study is unique in
that we not only verified biomarker levels in spinal cord tissue
and in CSF in rat model of SCI, but several candidate biomark-
ers were further validated in human CSF samples from day 0 to
6 post-SCI. Thus, the translational potential of our findings is
high. PEA-15 is especially of interest as it is highly specific to
astroglial cells found in the CNS, thus it might be a specific SCI
biomarker. The next step will be development of simple, robust
and quantitative assays (such as ELISA) for these biomarkers to
further validate their elevations not only in proximal biofluid such
as CSF, but can in blood samples (such as serum or plasma)
from human SCI patients. Through Systems Biology and path-
way analysis, our proteomic study also pointed to a number of
altered signaling or cellular pathways. Thus our approach of
FIG. 10. Three pathways identified as altered based on the 12 SCI biomarker candidate proteins as input. Based on 1 Biology pathway
analysis, (Fig. 9), three pathways were found to have the most interactions between these 12 candidate biomarkers: A, Cell growth and Aging;
B, Metabolic Dysfunction; and C, Neural Death. Original SCI biomarkers are in red ovals with blue aura. Additional interacting partner proteins
are in red ovals. Cell processes are in blue rectangles, disease pathway in purple rectangles, while regulation are annotated by gray arrows.
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differential SCI proteomics can facilitate not only the identifica-
tion of novel diagnostic and potentially prognostic SCI biomark-
ers. Although this study does provide novel information regard-
ing alterations in a battery of biomarkers after experimental and
human SCI, more work has to be done to completely charac-
terize these outcome measures. Indeed, larger groups of ani-
mals and subjects with different locations and degrees of injury
would help identify specific biomarkers for patients with specific
types of SCI. Thus, future studies will build on these observa-
tions and hopefully provide therapeutic targets for future treat-
ment interventions.
* This study is supported in part by the DOD grant W81XWH-12-
1-0276 (WDD, MSW) and W81XWH-12-1-0277 (KKW) from the United
States Army.
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FIG. 11. Systems Biology analysis identifying further interactome and interplay among the top 12 new SCI biomarkers with
additional CNS injury biomarkers II-spectrin (SPTAN1; SPAN2(mouse)), UCHL1 and MBP, GFAP, and S100b. Systems Biology
analysis was based on STRING program (http://string-db.org/) with action views using three species: human (A), mouse (B), and rat (C).
Blue lines indicate interactions, arrows indicate regulations, whereas gray lines identify possible associations. Green circles identified key
interaction clusters identified.
TABLE III
Spinal cord injury candidate biomarkers
Name Description
TF Transferrin
FASN Fatty acid synthase
NME1 NME/NM23 nucleoside diphosphate kinase 1
STMN1 Stathmin 1





PEA15 Phosphoprotein enriched in astrocytes 15
GOT2 Glutamic-oxaloacetic transaminase 2, mitochondrial
(aspartate aminotransferase 2)
TPI-1 Triosephosphate isomerase 1, TIM
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